Ranbaxy May Be Hit With Significant Disgorgement Penalty For GMP Violations
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Ranbaxy's long-running encounter with U.S. FDA over American regulatory allegations of significant deficiencies at two Ranbaxy manufacturing sites - Paonta Sahib and Dewas - may be headed for a settlement in coming months, with the Indian generics flag-bearer paying out several million dollars in penalties
You may also be interested in...
Is Ranbaxy Inching Closer To Resolution Of Its GMP Disputes With U.S. FDA?
MUMBAI - After more than two years of serious deliberations, Ranbaxy seems to be finally moving forward to resolve charges of significant manufacturing lapses leveled by U.S. FDA at two of its India-based sites
Is Ranbaxy Inching Closer To Resolution Of Its GMP Disputes With U.S. FDA?
MUMBAI - After more than two years of serious deliberations, Ranbaxy seems to be finally moving forward to resolve charges of significant manufacturing lapses leveled by U.S. FDA at two of its India-based sites
Ranbaxy Set To launch Aricept Generic In U.S. As FDA OKs Ohm Labs Data; Will Lipitor Be Next ?
MUMBAI - India's largest drug maker Ranbaxy - now part of Japanese pharma Daiichi Sankyo - is set to launch a generic version of the blockbuster Alzheimer's disease drug Aricept (donepezil) in the U.S. market, leading experts to predict that Ranbaxy may also be on track to launch a generic of the world's best selling drug, Lipitor (atorvastatin)